Title of the talk​

Alternatives to antibiotics for multidrug resistant infections.

R.E.W. (Bob) Hancock OC, OBC, FRSC. He is a UBC Killam Professor of Microbiology & Immunology, and a Canada Research Chair in Health and Genomics. His research interests include small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections, the systems biology of innate immunity, inflammatory diseases, sepsis, and Pseudomonas aeruginosa, and antibiotic uptake and resistance (http://cmdr.ubc.ca/bobh/). He has published more than 770 papers and reviews, has 65 patents awarded, and is a Clarivarate highly cited author in Microbiology with more than 108,000 citations and an h-index of 166. Recently he was ranked by in the world’s 250 most highly cited researchers (PLoS Biol 18(10):e3000918, 2020). He has won several awards including the ICAAC Aventis Antimicrobial Research Award, the leading award for research on antimicrobials, and Canada’s three top prizes for Health Research, and is an Officer of the Order of Canada. He was a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset Biotherapeutics, and the Centre for Drug Research and Development.